Clinical trial · Interventional
Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes
Enhanced Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Post-Trans-arterial Chemoembolization: A Prospective Study Using Twin Internally Cooled-Perfusion Electrodes
NCT07192172CI-TRIAL-00107877ERFAcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This single-center, prospective study evaluates the therapeutic outcomes of saline-augmented bipolar radiofrequency ablation (RFA) with twin internally cooled-perfusion (TICP) electrodes for treating recurrent hepatocellular carcinoma (HCC) following trans-arterial chemoembolization (TACE).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Neoplasms | Liver Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Experimental: Bipolar RFA using TICP electrodes
- description
- All participants receive bipolar RFA treatment using TICP electrodesTreatment is conducted under real-time ultrasound-CT/MR fusion guidance
- interventionNames
- Device: Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes
Primary outcomes (1)
- measure
- 2-year cumulative incidence of local tumor progression (LTP)
- timeFrame
- Time Frame: 2 years
- description
- 2-year cumulative incidence of local tumor progression (LTP) Description: LTP defined as the appearance of enhancement at the ablation margin on contrast-enhanced imaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 20-85 years Child-Pugh Class A liver function Radiologically confirmed locally recurrent HCC following conventional TACE treatment Recurrent HCC defined as arterially enhancing tumor at the edge of treated tumor Exclusion Criteria: * More than three HCC nodules Tumors with ≥5 mm abutment length to main hepatic veins or first branches of main portal vein HCC nodules ≥3 cm Platelet count ≤50,000/mm³ or INR prolongation ≥50% Extrahepatic metastasis or vascular invasion Child-Pugh class B or C ECOG performance status ≥3 Poor acoustic window or inability to achieve percutaneous access
References
Publications (1)
- BACKGROUNDChoi JW, Lee JM, Lee DH, Yoon JH, Kim YJ, Lee JH, Yu SJ, Cho EJ. Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. Korean J Radiol. 2021 Feb;22(2):179-188. doi: 10.3348/kjr.2020.0134. Epub 2020 Jul 22. PMID 32729269